Evidence map›Paper›PMID 34999740›Full record

ArticleAmerican journal of clinical pathology2022

High-Throughput Adaptable SARS-CoV-2 Screening for Rapid Identification of Dominant and Emerging Regional Variants.

Zita Hubler, Xiao Song, Cameron Norris, Mehul Jani, David Alouani, Maureen Atchley, Lisa Stempak, Sarah Cherian, Christine Schmotzer, Navid Sadri

Open access · bronzeAbstract read
In one paragraph

Article in American journal of clinical pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Zita HublerDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Xiao SongDepartment of Pathology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Cameron NorrisDepartment of Pathology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Mehul JaniDepartment of Pathology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
David AlouaniDepartment of Pathology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Maureen AtchleyDepartment of Pathology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Lisa StempakDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Sarah CherianDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Christine SchmotzerDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Navid SadriDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.ORCID 0000-0001-5051-717X
University Hospitals of Cleveland · USUniversity School · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4M
NRSA Training CoreTL1TR002549 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI HARDING, CLIFFORD V · 2018 to 2022
$2.9M
Novel targets in the cholesterol biosynthesis pathway for enhanced oligodendrocyte formationF30MH116581 · NIMH · CASE WESTERN RESERVE UNIVERSITY · PI HUBLER, ZITA MARIA LUPE · 2018 to 2021
$195k
NCATS NIH HHS TL1 TR002549NIGMS NIH HHS T32 GM007250NIMH NIH HHS F30 MH116581
6 · The paper itself

Abstract

objectivesEmerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant strains can be associated with increased transmissibility, more severe disease, and reduced effectiveness of treatments. To improve the availability of regional variant surveillance, we describe a variant genotyping system that is rapid, accurate, adaptable, and able to detect new low-level variants built with existing hospital infrastructure.

methodsWe used a tiered high-throughput SARS-CoV-2 screening program to characterize variants in a supraregional health system over 76 days. Combining targeted reverse transcription-polymerase chain reaction (RT-PCR) and selective sequencing, we screened SARS-CoV-2 reactive samples from all hospitals within our health care system for genotyping dominant and emerging variants.

resultsThe median turnaround for genotyping was 2 days using the high-throughput RT-PCR-based screen, allowing us to rapidly characterize the emerging Delta variant. In our population, the Delta variant is associated with a lower cycle threshold value, lower age at infection, and increased vaccine-breakthrough cases. Detection of low-level and potentially emerging variants highlights the utility of a tiered approach.

conclusionsThese findings underscore the need for fast, low-cost, high-throughput monitoring of regional viral sequences as the pandemic unfolds and the emergence of SARS-CoV-2 variants increases. Combining RT-PCR-based screening with selective sequencing allows for rapid genotyping of variants and dynamic system improvement.

Indexed as

COVID-19SARS-CoV-2High-Throughput Screening AssaysHumansPandemicsDelta variantE484KSARS-CoV-2Targeted testingVariant identificationVariant of concernVariant screening

Identifiers

PMID34999740
PMCPMC8755384
OpenAlexW4226065237

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.